Guillain-Barré syndrome: natural history and prognostic factors: a retrospective review of 106 cases

Inés González-Suárez, Irene Sanz-Gallego, Francisco Javier Rodríguez de Rivera, Javier Arpa, Inés González-Suárez, Irene Sanz-Gallego, Francisco Javier Rodríguez de Rivera, Javier Arpa

Abstract

Background: Guillain-Barre syndrome (GBS) is characterized by acute onset and progressive course, and is usually associated with a good prognosis. However, there are forms of poor prognosis, needing ventilatory support and major deficits at discharge. With this study we try to identify the factors associated with a worse outcome.

Methods: 106 cases of GBS admitted in our hospital between years 2000-2010 were reviewed. Epidemiological, clinical, therapeutical and evolutionary data were collected.

Results: At admission 45% had severe deficits, percentage which improves throughout the evolution of the illness, with full recovery or minor deficits in the 87% of patients at the first year review. Ages greater than 55 years, severity at admission (p < 0.001), injured cranial nerves (p = 0.008) and the needing of ventilator support (p = 0.003) were associated with greater sequels at the discharge and at the posterior reviews in the following months. 17% required mechanical ventilation (MV). Values < 250 L/min in the Peak Flow-test are associated with an increased likelihood of requiring MV (p < 0.001).

Conclusions: Older age, severe deficits at onset, injured cranial nerves, requiring MV, and axonal lesion patterns in the NCS were demonstrated as poor prognostic factors. Peak Flow-test is a useful predictive factor of respiratory failure by its easy management.

References

    1. Van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 2008;7:939–950. doi: 10.1016/S1474-4422(08)70215-1.
    1. Vucic S, Kiernan MC, Cornblath DR. Guillain-Barré syndrome: An update. J Cli Neurosci. 2009;16:733–741. doi: 10.1016/j.jocn.2008.08.033.
    1. Tellería-Díaz A, Calzada-Sierra DJ. Síndrome de Guillain-Barré. Rev Neurol. 2002;34(10):966–976.
    1. Asbury AK, Arnason BGW, Karp HR, McFarlin DF. Criteria for diagnosis of Guillain-Barré syndrome. Ann Neurol. 1978;3:565–566.
    1. Asbury AK, Cornblath DR. Assesment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 1990;27(Suppl):S21–S24.
    1. Hughes RAC, Rees JH. Clinical and epidemiologic features of Guillain-Barré syndrome. J Infect Dis. 1997;176(suppl2):S92–S98.
    1. Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R. et al.Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29:599–612. doi: 10.1016/j.vaccine.2010.06.003.
    1. McGrogan A, Madle G, Seaman HE, De Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. Neuroepidemiology. 2009;32:150–163. doi: 10.1159/000184748.
    1. The Emilia-Romagna Study group on Clinical and Epidemiological Problems in Neurology. A prospective study on the incidence and prognosis of Guillain-Barré syndrome in Emilia-Romagna region, Italy (1992–1993) Neurology. 1997;48:214–221.
    1. Lyu R-K, Tang L-M, Cheng S-Y, Hsa W-C, Chen S-T. Guillain-Barré syndrome in Taiwan: a clinical study of 167 patients. J Neurol Neurosurgery Psychiatry. 1997;63:494–500. doi: 10.1136/jnnp.63.4.494.
    1. Cuadrado JI, de Pedro Cuesta J, Ara JR, Cemillan CA, Díaz M, Duarte J. et al.Guillain-Barré syndrome in Spain, 1985–1997: epidemiological and public health view. Eur Neurol. 2001;46:83–91. doi: 10.1159/000050769.
    1. Alandro-Benito Y, Conde-Sendín MA, Muñoz-Fernández C, Pérez-Correa S, Alemany-Rodríguez MJ, Fiuza-Pérez MD. et al.Síndrome de Guillain-Barré en el área norte de Gran Canaria e isla de Lanzarote. Rev Neurol (Barc.) 2002;35:705–710.
    1. Soysal A, Aysal F, Caliskan B, Dogan Ak P, Mutluay B, Sakalli N. et al.Clinico-electrophysiological findings and prognosis of Guillain-Barré syndrome - 10 years’experience. Acta Neurol Scand. 2011;123:181–186. doi: 10.1111/j.1600-0404.2010.01366.x.
    1. The Italian Guillain-Barré Study Group. The prognosis and main prognostic indicators of GuillainBarré syndrome. A multicentre prospective study of 297 patients. Brain. 1996;119:2053–2061.
    1. Van Koningsveld R, Steyerberg EW, Hughes RAC, Swan AV, Van Doorn PA, Jacobs BC. A clinical prognostic scoring system of Guillain-Barré syndrome. Lancet Neurol. 2007;6:589–594. doi: 10.1016/S1474-4422(07)70130-8.
    1. Chodwury D, Arora A. Axonal Guillain Barré syndrome: a critical review. Acta Neurol Scand. 2001;103:267–277.
    1. Mori M, Kuwaraba S, Fukutake T, Yuki N, Hattori T. Clinical features and prognosis of Miller Fisher syndrome. Neurology. 2001;56:1104–1106. doi: 10.1212/WNL.56.8.1104.
    1. Korinthenberg R, Schessl J, Kirschner J. Clinical presentation and course of childhood Guillain-Barré syndrome: a prospective multicentre study. Neuropediatrics. 2007;38:10–17. doi: 10.1055/s-2007-981686.
    1. Lawn ND, Fletcher DD, Henderson RD, Wolter TD, Wijdicks EF. Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol. 2001;58:871–872. doi: 10.1001/archneur.58.6.871.
    1. Durand MC, Porcher R, Orlikowski D, Aboab J, Devaux C, Clair B. et al.Clinical and electrophysiological predictors of respiratory failure in Guillain-Barré syndrome: a prospective study. Lancet Neurol. 2006;5:1021–1028. doi: 10.1016/S1474-4422(06)70603-2.
    1. Ropper AH, Widjicks EFM, Truax BT, editor. Guillain- Barré syndrome. Philadelphia: F.A. Davis; 1991.
    1. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polineuropathy. Lancet. 1978;2:750–753.
    1. Hadden RDM, Cornblath DR, Hughes RAC, Zielasek J, Hartung HP, Toyka K. et al.Electrophysiological classification of Guillain-Barré Syndrome: clinical associations and outcome. Ann Neurol. 1998;44:780–788. doi: 10.1002/ana.410440512.
    1. Hughes RAC, Cornblath DR. Guillain-Barré syndrome. Lancet Neurol. 2005;366:1653–1666. doi: 10.1016/S0140-6736(05)67665-9.
    1. Hadden RD, Karch H, Hartung HP, Zielasek J, Weissbrich B, Schubert J. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology. 2001;56:758–765. doi: 10.1212/WNL.56.6.758.
    1. Saifudheen K, Jose J, Gafoor VA, Musthafa M. Guillain-Barré síndrome and SIADH. Neurology. 2011;76:701–704. doi: 10.1212/WNL.0b013e31820d8b40.
    1. Van den Bergh PYK, Piéret F. Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2004;29:565–574. doi: 10.1002/mus.20022.
    1. Vucic S, Cairns KD, Black KR, Chong PST, Cros D. Neurophysiologic findings in early acute inflammatory demyelinating polyradiculoneuropathy. Clin Neurophysiology. 2004;115:2329–2335. doi: 10.1016/j.clinph.2004.05.009.
    1. Alam TA, Chaudhry V, Cornblath DR, Alam TA, Chaudhry V, Cornblath DR. Electrophysiological studies in the Guillain-Barré syndrome: 30. Electrophysiological studies in the Guillain-Barré syndrome: distinguishing subtypes by published criteria. Muscle Nerve. 1998;21:1275–1279. doi: 10.1002/(SICI)1097-4598(199810)21:10<1275::AID-MUS5>;2-8.
    1. Jamal GA, Leod Mac WN. Electrophysiologic studies in Miller Fisher syndrome. Neurology. 1984;34:685–688. doi: 10.1212/WNL.34.5.685.
    1. Lo YL. Clinical and immunological spectrum of the Miller Fisher syndrome. Muscle Nerve. 2007;36:615–627. doi: 10.1002/mus.20835.
    1. Yuki N. Fisher syndrome and Bickerstaff brainstem encephalitis (Fisher-Bickerstaff syndrome) J Neuroimmunol. 2009;215:1–9. doi: 10.1016/j.jneuroim.2009.05.020.
    1. Rajabally YA, Unicini A. Outcome and its predictors in Guillain-barré syndrome. J Neurol Neurosurg Psychiatry. 2012;83:711–718. doi: 10.1136/jnnp-2011-301882.
    1. Walgaard C, Lingsma HF, Ruts L. et al.Early recognition of poor prognosis in Guillain-Barré syndrome. Neurology. 2011;76:968–975. doi: 10.1212/WNL.0b013e3182104407.
    1. Suarez AA, Pessolano FA, Monteiro SG, Ferreyra G, Capria ME, Mesa L. et al.Peak flow and peak cough flow in the evaluation of expiratory muscle weakness and bulbar impairment in patients with neuromuscular disease. Am J Phys Med Rehabil. 2002;81:506–511. doi: 10.1097/00002060-200207000-00007.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться